- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Dana Goldman Outlines How to Meet the Needs of Patients With Mental Illness
Patients with mental illness can be a very difficult population to treat and programs need to be established that properly meet the health needs of these patients, said Dana Goldman, PhD.
the Leonard D. Schaeffer Chair and Director of the Schaeffer Center for Health Policy and Economics at the University of Southern California
Patients with mental illness can be a very difficult population to treat and programs need to be established that properly meet the health needs of these patients, said Dana Goldman, PhD, .
Transcript (modified)
Schizophrenics in states with prior authorization requirements were 22% more likely to be jailed for a non-violent crime than their counterparts in states without those requirements. What policy changes are needed to appropriately meet the health needs of schizophrenic patients?
This is a real problem for society. We need to get these patients into care—they’re a very hard population to treat.
Severe mental illness is a real public burden and so we need to figure out programs that house this population, get them into care, get them stabilized on medication, and ensure that when they leave the psychiatric care system that they’re appropriately followed.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
For Patients Who Cannot Wait, This Off-the-Shelf CAR NK Treatment for AML Leaves Healthy Cells Alone
May 12th 2025First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research Institute. Strickland recently presented data from a phase 1 trial of SENTI-202, an investigational chimeric antigen receptor (CAR) natural killer (NK) cell therapy.
Read More
